Radical Radiation Therapy for Prostate Cancer in Japan: a Patterns of Care Study Report
|
|
- Kerry Peters
- 5 years ago
- Views:
Transcription
1 Jpn J Clin Oncol 2003;33(3) Original Articles Radical Radiation Therapy for Prostate Cancer in Japan: a Patterns of Care Study Report Katsumasa Nakamura 1, Teruki Teshima 2, Yutaka Takahashi 2, Atsushi Imai 3, Masahiko Koizumi 4, Norio Mitsuhashi 5, Toshihiko Inoue 3 and Japanese PCS Working Subgroup of Prostate Cancer 1 Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 2 Department of Medical Engineering, Osaka University Faculty of Medicine, Suita, Osaka, 3 Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, 4 Department of Radiation Therapy, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka and 5 Department of Radiology, Tokyo Women s Medical University, Tokyo, Japan Received July 24, 2002; accepted January 31, 2003 Background: The patterns of radical radiation therapy for prostate cancer are unclear in Japan. A Patterns of Care Study was performed throughout Japan to examine the patterns of radiation therapy for prostate cancer. Methods: From 1999 to 2000, extramural audits were performed on 50 randomly selected institutions (~7% of all institutions in Japan). Detailed information was collected on a total of 311 prostate cancer patients without evidence of distant metastases, who were treated by radiation therapy between 1996 and Of these 311 patients, 162 treated radically using photon beams were analyzed in this study. Results: Eighty percent of the patients had high-risk diseases defined as T3 or T4 tumors, a pretreatment prostate-specific antigen level >20 ng/ml or poorly differentiated adenocarcinoma. Androgen ablation was performed in 85.8% of patients and the median duration of hormonal therapy before and after radiation therapy was 5.3 and 21.4 months, respectively. The median total dose of radiation therapy to the prostate was 65.0 Gy (range: Gy). The 3-year overall and biochemical relapse-free survival rates were 86.7 and 86.1%, respectively. Late toxicity was mild, with only nine patients (5.6%) exhibiting grade 2 late morbidity. Conclusions: The majority of the patients who received radical radiation therapy in Japan have high-risk disease. Androgen ablation plus radiation therapy was commonly used to treat these patients and resulted in high rates of initial control with a low risk of complications. Key words: prostate cancer radiation therapy Patterns of Care Study INTRODUCTION The incidence rate and death rate for prostate cancer is low in Asian countries (1). In the 1980s, four per men died of prostate cancer in Japan, whereas in Western Europe and North America the annual mortality rate ranged from 16 to 18 per men (2). Gu et al. reported that the incidence of and mortality from prostate cancer in China was about 20 times less than that observed in Western countries (3). However there For reprints and all correspondence: Katsumasa Nakamura, Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3 1 1, Higashi-ku, Fukuoka , Japan. nakam@radiol.med.kyushu-u.ac.jp are few reports on the treatment of prostate cancer with radiation therapy in Asia and the patterns of treatment have not been previously examined. In Asian countries, most patients with prostate cancer have high-risk disease. Zhau et al. (4) reported that 74.5% of Chinese patients with adenocarcinoma of the prostate had poorly differentiated disease, compared with 28.6% of patients in the United States. A study of 95 patients treated in a Thailand hospital reported that 7.5% had stage A disease, 1.1% stage B, 67.7% stage C and 23.7% stage D (5). In contrast, most of patients in the United States have localized prostate cancers (6). Because of the interracial differences in the pathologic features and clinical manifestation of prostate cancer, it is valuable to examine the patterns of the treatment in Asia, 2003 Foundation for Promotion of Cancer Research
2 Jpn J Clin Oncol 2003;33(3) 123 which may be affected by cultural, racial, ethnic or social background. The Patterns of Care Study (PCS), a widely known quality assurance program in the USA (7), was conducted in Japan (8) in an attempt to obtain data on the national standards of radiation therapy for several diseases. The purpose of this study was to examine the patterns of radical treatment of prostate cancer with radiation therapy, as the mortality rates are lower and radiation therapy is less frequently employed than in Western countries. Patient outcome was also assessed. The majority of these patients were treated by a combination of radiation therapy and hormonal therapy. PATIENTS AND METHODS The methods used in data collection for the PCS have been described previously (9). From a stratified Facilities Master list, a random sample of radiation therapy facilities was selected. Each of the 50 randomly chosen facilities was visited from 1999 to 2000 and a total of up to 20 medical records from each institute were randomly selected and reviewed. The following eligibility criteria were used in the process survey: the patients were required to have adenocarcinoma of the prostate without evidence of distant metastases; they must have been treated with radiation therapy between January 1996 and December 1998; and they must not have been diagnosed with any other malignancy or have been previously treated with radiation therapy. Patients who had a radical prostatectomy or hormonal therapy prior to radiation therapy were included in this survey. The total number of prostate cancer patients surveyed was 311, which included 162 patients treated with radical radiation therapy using photon beams, 69 patients treated after prostatectomy, 61 patients who received radiation therapy after progression on hormonal therapy, 14 patients treated with high-dose rate brachytherapy and five patients treated with protons. For simplification of analysis, the patterns of treatment and outcome of 162 patients treated with radical radiation therapy using photon beams are reported here. The results from patients with hormone-refractory or surgically removed cancers will be published elsewhere. The patients analyzed here were treated in 36 institutions. Of them, 87 were treated at 14 A1 institutions (university hospital/ cancer center treating 300 patients/year), 35 were treated at 10 A2 institutions (university hospital/cancer center treating <300 patients/year), 30 were treated at eight B1 institutions (other institutions treating 120 patients/year) and 10 were treated at four B2 institutions (other institutions treating <120 patients/year). Biochemical relapse-free survival was defined by the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus definition (10). Clinical relapse was determined by physical examination, biopsy or radiological findings. The overall survival rate and the biochemical relapsefree survival rate were calculated using the Kaplan Meier Table 1. Patients and disease characteristics No. patients 162 Age (years) Median 70 Range Differentiation Well 24 (14.8%) Moderate 80 (49.4%) Poor 45 (27.8%) Unknown 13 (8.0%) T-Stage/1997 UICC T1 8 (4.9%) T2 47 (29.0%) T3 81 (50.0%) T4 22 (13.6%) Unknown 4 (2.5%) N-Stage/1997 UICC N0 131 (80.9%) N1 18 (11.1%) Unknown 13 (8.0%) Pretreatment PSA level (ng/ml) Median 22.0 Range PSA, prostate-specific antigen; UICC, International Union Against Cancer. method. The Radiation Therapy Oncology Group (RTOG) late toxicity scales were used to assess the late morbidity. RESULTS PATIENTS AND DISEASE CHARACTERISTICS Patients characteristics are shown in Table 1. More than 60% of the patients had T3 or T4 tumors. The median prostatespecific antigen (PSA) level was >20 ng/ml. Only 14.8% of patients had well differentiated adenocarcinoma. The number of high-risk patients, defined as either T3 or T4 tumors, a pretreatment PSA level >20 ng/ml or poorly differentiated tumors, was 130 (80.2%). TREATMENT The reasons for the particular choice of radiation therapy given to these patients are shown in Table 2. Most of the cases were treated with radiation therapy because of their advanced stage or old age. Only 4.9% of the patients received radiation therapy because of the patients wishes. The treatment characteristics are shown in Table 3. Over 80% of patients received a combination of radiation therapy and hormonal therapy. Luteinizing hormone-releasing agonists
3 124 Radiotherapy for prostate cancer Table 2. Percentage of reason for selection of radiation therapy Advanced stage 44 (27.2%) Old age 37 (22.8%) Patient choice 8 (4.9%) Medical contraindication 7 (4.3%) Others 8 (4.9%) Unknown 58 (35.8%) and antiandrogen agents were frequently used, but estrogen agents were given in 11.1% of patients. Orchiectomy was performed in 9.9% of patients. Hormonal therapy was performed before, during and after radiation therapy in 74.7, 68.5 and 66.7% of patients, respectively. The median duration of hormonal therapy before and after radiation therapy was 5.3 and 21.4 months, respectively. Regarding radiation therapy, a linear accelerator of 10 MV was used in two-thirds of patients. Patients were treated with a variety of radiation therapy techniques. The treatment plan included a moving field in 40.1% of patients. More than twothirds of conformal therapy was performed with a rotational conformation using a dynamic multileaf collimator. The median dose delivered to the prostate was 65.0 Gy (range: Gy). The median daily fraction size to the prostate was 200 cgy (range: cgy). Most (83.5%) patients received doses of cgy per day. The patients treated with conformal and conventional radiation therapy were irradiated with a median dose of 65.0 and 60.0 Gy, respectively. Pelvic irradiation was performed in about half of the patients. OUTCOME At a median follow-up of 27.5 months, five patients had died of prostate cancer, two of cerebrovascular diseases and two of other unknown causes. Biochemical failure was noted in 17 patients. Clinically, local progression was observed in five patients and distant metastases were seen in 10. No regional lymph node metastases were observed. The 3-year overall and biochemical relapse-free survival rates were 86.7 and 86.1%, respectively (Fig. 1). Late morbidity of RTOG grade 2 was seen in nine patients (5.6%). There were no cases of grade 3 4 toxicity. Three of these patients were treated with conformal therapy and six with conventional therapy. Rectal bleeding was seen in six patients and hematuria, incontinence or urethral stricture in three patients. DISCUSSION The present study revealed that the majority of patients with prostate cancer who received radical radiation therapy in Japan had high-risk disease. The radiation doses employed were lower than those typically used in the USA. However, radiation therapy was commonly combined with hormonal therapy. Table 3. Treatment characteristics Hormonal therapy Yes 139 (85.8%) Content Orchiectomy 16 (9.9%) Estrogen agent 18 (11.1%) LH-RH agonist 113 (69.8%) Antiandrogen 94 (58.0%) Period (median) Before RT 121 (74.7%) (4.9 months) During RT 111 (68.5%) After RT 108 (66.7%) (21.4 months) Radiation therapy Energy <10 MV 56 (34.6%) 10 MV 63 (38.9%) >10 MV 31 (19.1%) Unknown 12 (7.4%) Field arrangement for the prostate Anterior-posterior 30 (18.5%) 4 field 43 (26.5%) >4 field 4 (2.5%) Moving 65 (40.1%) Others 8 (4.9%) Unknown 12 (7.4%) Conformal therapy Yes 80 (49.4%) Rotational 62 (38.3%) Static 18 (11.1%) Pelvic irradiation Yes 70 (43.2%) LH-RH, luteinizing hormone-releasing hormone; RT, radiation therapy. Although the follow-up period was short, the combination therapy seemed to be effective, with little risk of tissue complications. However, this is a preliminary study for future outcome analysis. Although the survival of the patients seems to be excellent, we should keep in mind that the outcome in the present study may have been affected by the short follow-up period and patients lost to follow-up. Longer follow-up is required to confirm the trends seen in this preliminary report. It is acknowledged that conventional radiation alone has little curative potential in high-risk prostate cancer (defined as a pretreatment PSA level >20 ng/ml, a Gleason score of 8 10 or stage T3 T4 disease) (11). A meta-analysis of RTOG prostate cancer trials in the USA suggested that patients in these high-risk groups may experience a substantial improvement in overall and disease-specific survival with a combination of
4 Jpn J Clin Oncol 2003;33(3) 125 Figure 1. (a) Overall survival and (b) biochemical relapse-free survival curves for prostate cancer patients treated with radical radiation therapy. radiation therapy and long-term hormonal therapy (12). Taking into account the high percentage of high-risk patients in this study, the therapeutic strategy of long-term androgen suppression with radiation therapy may be appropriate for a majority of Japanese patients. However, prolonged androgen ablation may lead to side effects such as impotence, hot flushes, fatigue and osteoporosis. Questions concerning the optimal timing and duration of androgen ablation should be addressed in future studies. Estrogen therapy is associated with serious side effects with, in particular, an increased risk of cardiovascular complications reported for patients in Western countries (13). However, 11.1% of patients in this study were treated with estrogen agents. Because cardiovascular complications appear to be a relatively rare side effect of estrogen therapy in Japan (14,15), estrogen administration remains an option for androgen suppression. However, it should be noted that the increase in serum cholesterol in Japan may affect the future rates of coronary heart disease (16). The radiation doses employed in Japanese institutions were lower than those typically used in the USA. External beam radiation alone, in modest doses of Gy, is insufficient to eradicate prostate tumors (17). PCS studies in the USA revealed that the median radiation dose employed had increased from 66 to 68.4 Gy between 1978 and 1994 (18). There had also been a dramatic decrease in the use of adjuvant hormonal therapy, from 59% in 1978 to 9% in 1994 (19). However, it should be noted that, in contrast to Japanese patients, most of the patients in the USA have T1 T2 diseases with lower pretreatment PSA levels (18). Patients with unfavorable prognostic features, who may have micrometastatic disease, are not ideal candidates for dose-escalation studies and should be treated by combination treatment. It is well known that radiation dose is a strong, independent predictor of failure (17). However, if radiation therapy is combined with long-term androgen ablation, which may have synergistic effects with radiation therapy (19), higher doses may not have a major impact on local control. In fact, although the median dose delivered in this series was 65.0 Gy, local failure was seen in only five patients (3.1%). However, the optimal dose in these patients remains to be defined. The survey results indicated that treatments were delivered frequently using rotational conformal techniques. This technique may be popular in Japan because conformal radiation therapy using rotation techniques was developed by Takahashi (20). However, only modest doses were delivered to the prostate and an advantage of conformal therapy was not demonstrated in this survey. There is great controversy regarding the effectiveness of elective radiation therapy of the pelvic lymphatics in patients with high-risk prostate cancer. The prospective randomized trials conducted by the Radiation Therapy Oncology Group (RTOG 75 06, 77 06) showed no better survival for patients who received pelvic or paraaortic irradiation (21,22). Therefore, pelvic irradiation was no longer advocated. However, reanalysis showed several problems with the study design (23). For example, patients with T1 T2 diseases, who were not at high risk of pelvic lymph node metastases, were investigated in RTOG (22). In contrast, the preliminary analysis of a recent randomized trial (RTOG 9413) has demonstrated that pelvic irradiation is associated with an improvement in the progression-free survival in patients with an estimated risk of lymph node metastases >15% (24). In the present study, pelvic irradiation was performed in 43.2% of patients, although the majority of patients had high-risk disease. Each radiation oncologist has to make his or her own decision regarding pelvic radiotherapy as there is no standard treatment. In the near future, this issue will be addressed. This PCS study showed that only 4.9% of the patients chose radiation therapy as their treatment of choice. In most cases, patients were treated with radiation therapy because of old age or advanced cancer stage. This is because Japanese patients rarely ask for a second opinion from a radiation oncologist in Japan. However, this is changing rapidly. Patients have become more informed about the available treatment options and the general public has become more aware of the advantages of radiation therapy. The number of patients with prostate cancer is still small, but increasing very rapidly, in Asian counties (1). In Japan, the incidence of prostate cancer in 1996 was reported to be double that observed in 1980 (25). In addition, screening for prostate
5 126 Radiotherapy for prostate cancer cancer using PSA has been introduced (26), leading to the detection of patients with early-stage prostate cancer. The standard treatment of care for prostate cancer used to be either prostatectomy or hormonal therapy in Japan. In particular, hormonal therapy was commonly utilized, in part because of the considerable number of prostate cancer patients with advanced disease or poorly differentiated tumors. However, the use of radical radiation therapy is being increasingly accepted as an alternative option for the curative treatment of these cancers (27) and early-stage prostate cancer will be treated by radiation therapy more frequently in the near future. This report serves to delineate the patterns of radiation therapy for prostate cancer in Japan between 1996 and However, the characteristics of prostate cancer and the patterns of radiation therapy in Japan are changing rapidly, resulting in the recent initiation of a new series of Patterns of Care Studies. Acknowledgments This study was supported in part by a Grant-in Aid for Cancer Research (Nos and 14-6) from the Ministry of Health, Labor and Welfare and a Grant from Japan Society for the Promotion of Sciences. We thank all radiation oncologists who participated in this study. Their efforts in providing us with information makes these surveys possible. This paper was presented in part at the 87th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Chicago, IL, November References 1. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85: Parker SL, Davis KJ, Wingo PA, Ries LA, Heath CW Jr. Cancer statistics by race and ethnicity. CA Cancer J Clin 1998;48: Gu FL, Xia TL, Kong XT. Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China. Urology 1994;44: Zhau HE, Zhao LS, Chen BQ, Kojima M. Interracial comparative study of prostate cancer in the United States, China and Japan. J Cell Biochem Suppl 1997;28 29: Soontrapa S, Tantiwong A, Leewansangtong S, Bhanalaph T. Five-year follow-up of prostate cancer in Siriraj Hospital. J Med Assoc Thai 2000; 83: Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, et al. Prostate Cancer Trends , SEER Program, National Cancer Institute. NIH Publication No Bethesda, MD: National Institutes of Health, Hanks GE, Coia LR, Cury J. Patterns of care studies past, present and future. Semin Radiat Oncol 1997;7: Teshima T. Patterns of care study in radiation oncology history, methodology and important results in the United States. J Jpn Soc Ther Radiol Oncol 1999;11: (in Japanese). 9. Teshima T, Abe M, Ikeda H, Hanks GE, Owen JB, Hiraoka M, et al. Patterns of Care Study of radiation therapy for esophageal cancer in Japan: influence of the stratification of institution on the process. Jpn J Clin Oncol 1998;28: ASTRO consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37: Pollack A, Zagars, GK. Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit? Semin Radiat Oncol 1998;8: Roach M III, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, et al. Predicting long-term survival and the need for hormonal therapy: a metaanalysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47: Byar DP. The Veterans Administration Cooperative Urological Research Group s studies of cancer of the prostate. Cancer 1997;32: Kumamoto Y, Tsukamoto T, Umehara T. Clinical studies on endocrine therapy for prostatic carcinoma (2): prognosis of patients with prostatic carcinoma given endocrine therapy and analyses on causes of death and side effect of endocrine therapy. Acta Urol Jpn 1990;36: (in Japanese). 15. Sakai H, Minami Y, Kanetake H, Saito Y, Ito K, Suzuki T, et al. Endocrine therapy for prostate cancer: Nishinihon J Urol 1995;57: (in Japanese). 16. Kitamura A, Iso H, Iida M, Naito Y, Sato S, Jacobs DR, et al. Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to Am J Med 2002;112: Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Biol Phys 1997;39: Hanks GE, Teshima T, Pajak TF. 20 years of progress in radiation oncology: prostate cancer. Semin Radiat Oncol 1997;7: Laverdiere J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37: Takahashi S. Conformation radiotherapy, rotation techniques as applied to radiography. Acta Radiol Suppl 1965;242: Pilepich MV, Krall JM, Johnson RJ, Sause WT, Perez CA, Zinninger M, et al. Extended field (periaortic) irradiation in carcinoma of the prostate analysis of RTOG Int J Radiat Oncol Biol Phys 1986;12: Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG Int J Radiat Oncol Biol Phys 1988;15: Wiegel T, Hinkelbein W. Locally advanced prostate carcinoma (T2b T4N0) without and with clinical evidence of local progression (TxN+) with lymphatic metastasis. Is radiotherapy for pelvic lymphatic metastasis indicated or not? Strahlenther Onkol 1998;174: Roach M, Lu JD, Lawton C, Hsu IC, Machtay M, Seider MJ, et al. A phase III trial comparing whole-pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: preliminary analysis of RTOG Int J Radiat Oncol Biol Phys 2001;51:3 (abstract). 25. Kakizoe T, Yamaguchi N, Mitsuhashi F, Koshiji M, Oshima A, Ohtaka M, editors. Cancer Statistics in Japan Tokyo: Foundation for Promotion of Cancer Research, 2001;48 9 (in Japanese). 26. Watanabe H. Mass screening program for prostatic cancer in Japan. Int J Clin Oncol 2001;6: Ikeda H, Kagami Y, Tokuue K, Sumi M. Results of a survey of current trends in radiotherapy for patients with the prostate cancer at 34 institutions in Japan. Hinyouki Geka 1999;12: (in Japanese).
Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan
Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan KATSUMASA NAKAMURA 1, TERUKI TESHIMA 2, YUTAKA TAKAHASHI 2, ATSUSHI IMAI 3, MASAHIKO KOIZUMI 4, NORIO MITSUHASHI 5, YOSHIYUKI SHIOYAMA
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationHIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
0022-5347/01/1663-0876/0 THE JOURNAL OF UROLOGY Vol. 166, 876 881, September 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED
More informationIntraoperative Radiation Therapy for
Frontiers ofradiation Therapy and Oncology Reprint Editors: J.M. Vaeth, J.L. Meyer, San Francisco, Calif. ~' Publishers: S.Karger, Basel Printed in Switzerland Vaeth JM, Meyer JL (eds): The Role of High
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationProject approved by the Fondo de investigaciones Socio Sanitarias (FISS). Resolution dated June 8, Official State Gazette: June 17, 2004.
Edition No. 01 Phase III randomized and multicenter trial of adjuvant androgen deprivation combined with high-dose 3-dimensional conformal radiotherapy in intermediate- or high-risk localized prostate
More informationThe use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials
British Journal of Cancer (2004) 90, 950 954 All rights reserved 0007 0920/04 $25.00 www.bjcancer.com Minireview The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective
More informationBiochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy
Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir October 2015, Volume: 7, Issue: 6, Pages: 1330-1335, DOI: 10.14661/1330 Biochemical progression-free survival in localized prostate cancer
More informationImpact of the duration of hormonal therapy following radiotherapy for localized prostate cancer
ONCOLOGY LETTERS 10: 255-259, 2015 Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer MITSURU OKUBO, HIDETUGU NAKAYAMA, TOMOHIRO ITONAGA, YU TAJIMA, SACHIKA
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationHow Should WeTreat Patients with Locally Advanced Prostate Cancer?
European Urology Supplements European Urology Supplements 2 (2003) 14 22 How Should WeTreat Patients with Locally Advanced Prostate Cancer? Malcolm Mason * Section of Oncology and Palliative Medicine,
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationANTICANCER RESEARCH 34: (2014)
Role of Novel Risk Classification Method, Prostate Cancer Risk Index (PRIX) for Clinically Localized Prostate Cancer Αfter High-dose-rate Interstitial Brachytherapy as Monotherapy KEN YOSHIDA 1, HIDEYA
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationThe Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer
55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationMonotherapy with Carbon Ion Radiation for Localized Prostate Cancer
Japanese Journal of Clinical Oncology Advance Access published May 30, 2006 Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Jun Shimazaki 1, Koichiro Akakura 1, Hiroyoshi Suzuki 1,
More informationProstate Cancer. 3DCRT vs IMRT : Hasan Murshed
Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity
More informationANTICANCER RESEARCH 26: (2006)
Low Pre-radiotherapy Prostate-specific Antigen Level is a Significant Predictor of Treatment Success for Postoperative Radiotherapy in Patients with Prostate Cancer TOMONARI SASAKI 1, KATSUMASA NAKAMURA
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationRadiation dose has been reported to be an important determinant
538 The Relationship of Increasing Radiotherapy Dose to Reduced Distant Metastases and Mortality in Men with Prostate Cancer Rojymon Jacob, M.D. 1 Alexandra L. Hanlon, Ph.D. 2 Eric M. Horwitz, M.D. 1 Benjamin
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationdoi: /j.ijrobp CLINICAL INVESTIGATION
CME doi:10.1016/j.ijrobp.2010.07.2004 Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 5, pp. 1293 1301, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More information20 Prostate Cancer Dan Ash
20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised
More informationUpdated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy for Locally and Locally Advanced
Clinical Urology High-Dose Rate Brachytherapy for Prostate Cancer International Braz J Urol Vol. 34 (3): 293-301, May - June, 2008 Updated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 4 FEBRUARY 1 28 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationPROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive
Prostate-Specific Antigen Doubling Times Are Similar in Patients With Recurrence After Radical Prostatectomy or Radiotherapy: A Novel Analysis By Bryan D. Leibman, Ozdal Dillioglugil, Peter T. Scardino,
More informationHORMONAL THERAPY COMBINED WITH RADIOTHERAPY IN LOCALLY ADVANCED PROSTATE CANCER
HORMONAL THERAPY COMBINED WITH RADIOTHERAPY IN LOCALLY ADVANCED PROSTATE CANCER Piotr Milecki 1, Zbigniew Kwias 2 1 Department of Radiotherapy, Great Poland Cancer Centre, ul. Garbary St. 15, 61-866 Poznań,
More informationMichael J. Zelefsky MD a,, W. Robert Lee MD b, Anthony Zietman MD c, Najma Khalid MS d, Cheryl Crozier RN d, Jean Owen PhD d, J.
Practical Radiation Oncology (2013) 3, 2 8 www.practicalradonc.org Original Report Evaluation of adherence to quality measures for prostate cancer radiotherapy in the United States: Results from the Quality
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationRadiotherapy (RT) Protocol for Prostate Cancer
Radiotherapy (RT) Protocol for Prostate Cancer CGMH-2010-02 *This document is aimed to set up RT protocols for prostate cancer. The treatment guideline for prostate cancer will not be covered here. A.
More informationfailure (FBF) rates were calculated using the Phoenix definition.
. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology GLEASON SCORES 8 10 PROSTATE CANCER TREATED WITH TRIMODAL THERAPY STOCK et al. BJUI BJU INTERNATIONAL Outcomes for patients with high-grade
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More information55 th Annual Meeting American Society for Radiation Oncology. Patients: Hope Guide Heal News Briefing
55 th Annual Meeting American Society for Radiation Oncology Patients: Hope Guide Heal News Briefing Sunday, September 22, 2013 4:45 p.m. 5:15 p.m. Colleen A.F. Lawton, MD, FASTRO 2013 ASTRO President
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationNEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING
NEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING RADICAL PROSTATECTOMY IN PATIENTS WITH STAGE T2 PROSTATIC CANCER Takeshi Uedal, Hiroomi Nakatsul, Shigeo Isaka2 and Jun Shimazaki2 1Urology, Kumagaya
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationAFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options
AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although
More informationAndrogen Ablation Following Radiotherapy in Patients with Localized Prostatic Carcinoma
Med. J. Cairo Univ., Vol. 81, No. 2, March: 101-107, 2013 www.medicaljournalofcairouniversity.com Androgen Ablation Following Radiotherapy in Patients with Localized Prostatic Carcinoma EL SAYED M. EL
More informationLewis Garvey Smith III, MD Reference List
Journal D'Souza WD, Lee HK, Palmer MB, Smith LG, Pollack A. Is intraoperative nomogram-based overplanning of prostate implants necessary? Int J Radiat.Oncol.Biol.Phys. 56[2], 462-467. 2003 Rosser CJ, Chichakli
More informationPROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER
PROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER Alberto Bossi Radiotherapy and Oncology Gustave Roussy, Villejuif, France PROSTATE CANCER, Radiotherapy IGRT RT + ADT: short vs
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationMOLECULAR AND CLINICAL ONCOLOGY 6: , TEELE KUUSK, KRISTIINA PULLIAINEN and MARKKU H. VAARALA
428 External beam radiation for the treatment of castration resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients TEELE KUUSK, KRISTIINA
More informationReview of Polish and international guidelines on hormonal therapy in localized prostate cancer
Review article NOWOTWORY Journal of Oncology 2016, volume 66, number 5, 403 407 DOI: 10.5603/NJO.2016.0071 Polskie Towarzystwo Onkologiczne ISSN 0029 540X www.nowotwory.edu.pl Review of Polish and international
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationAdjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG
Journal of Radiation Research, 2014, 55, 533 540 doi: 10.1093/jrr/rrt137 Advance Access Publication 1 January 2014 Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More information18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan
An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationProstate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
More informationRadiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices
Original original research Radiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices Michel Zimmermann, MD; * Daniel Taussky,
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationThe Central Role of Radiation in Prolonging Survival for High-Risk Prostate Cancer
The Central Role of Radiation in Prolonging Survival for High-Risk Prostate Cancer Dean A. Shumway, MD, and Daniel A. Hamstra, MD, PhD Abstract Prostate cancer represents a leading cause of cancer mortality
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationAnalysis of External Radiotherapy for Localized Prostatic Cancer
Hiroshima J. Med. Sci. Vol.37, No.2, 77-81, June, 1988 HIJM 37-13 77 Analysis of External Radiotherapy for Localized Prostatic Cancer Masayuki KAGEMOT0 1 l, Kouichi WADASAKI 1 l, Kouzo KASHIWAD0 1 l, Yutaka
More informationSRO Tutorial: Prostate Cancer Clinics
SRO Tutorial: Prostate Cancer Clinics May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible, and
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationOpen clinical uro-oncology trials in Canada
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES
More informationRadiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities
Radiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities Prostate cancer is predominately a disease of older men,
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationdoi: /s (03) CLINICAL INVESTIGATION
doi:10.1016/s0360-3016(03)01746-2 Int. J. Radiation Oncology Biol. Phys., Vol. 58, No. 4, pp. 1048 1055, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationINTRODUCTION PATIENTS AND METHODS. Jpn J Clin Oncol 2007;37(10) doi: /jjco/hym098
Jpn J Clin Oncol 2007;37(10)775 781 doi:10.1093/jjco/hym098 Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More informationSalvage Brachytherapy After External-Beam Irradiation for Prostate Cancer
Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer Review Article [1] February 01, 2004 By David C. Beyer, MD [2] The options available for patients with recurrent prostate cancer
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationdiagnosed by transrectal needle biopsy who completed 3DCRT alone be- Center, Philadelphia, Pennsylvania.
75 Evidence of Increased Failure in the Treatment of Prostate Carcinoma Patients Who Have Perineural Invasion Treated with Three-Dimensional Conformal Radiation Therapy Steven R. Bonin, M.D. 1 BACKGROUND.
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationHong-Gyun Wu, M.D., Charn Il Park, M.D., S ung Whan Ha, M.D., and Il Han Kim, M.D.
J. Korean Soc Ther Radiol Oncol 1999;17(1):108 112 1) S ign ifica nce of S uprac lav ic ula r Lymph Node Invo lve me nt o n Dete rm inat io n of Clin ica l Stag ing fo r Tho rac ic Es o phagea l Ca rc
More informationBRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update
BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Table of Contents Data Supplement 1: Additional Evidence Table(s) Table
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationClinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate
Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical
More information